How AI Is Transforming Patient Support Programs

Artificial intelligence has moved beyond experimentation and into everyday operations across healthcare. Patient support programs (PSPs) are increasingly leveraging AI to streamline processes, improve patient engagement, and generate insights that help pharmaceutical manufacturers better support patients throughout their treatment journey.

Yet, many pharmaceutical manufacturers are  approaching AI tactically rather than strategically. They are implementing individual tools without defining how AI will support broader patient experience and program goals.

The pharmaceutical manufacturers that will realize the greatest value from AI are not necessarily those deploying the most technology, but those developing a thoughtful AI strategy that aligns innovation with patient needs, operational excellence, and measurable outcomes.

For patient support leaders, the question is no longer whether AI belongs in a PSP; it’s how to use it to create a more proactive, personalized, and effective patient experience while preserving the human connection that remains central to healthcare.

Every PSP Needs an AI Strategy
As AI capabilities continue to evolve, PSPs face a growing risk of fragmented adoption. New technologies emerge almost weekly, promising increased efficiency, automation, and engagement.

Without a clear strategy, however, pharmaceutical manufacturers can easily find themselves implementing solutions that create complexity rather than value.

An effective AI strategy should begin with the patient journey. Where are patients experiencing friction? Where do support teams spend the most time on manual processes? Which barriers could be identified earlier? Where can technology improve speed, accuracy, or accessibility without diminishing the patient experience?

Answering these questions allows pharmaceutical manufacturers to move beyond technology for technology’s sake and focus on outcomes that matter: improved access, faster therapy initiation, stronger adherence, and improved patient experiences.

AI should not be viewed as a standalone capability; it should be embedded into the overall patient support strategy.

Moving from Reactive to Predictive Patient Support
Historically, most patient support programs have operated reactively. Patients encounter a challenge, contact a support center, and receive assistance after the issue has already affected their treatment journey.

AI creates opportunities to fundamentally change that model. Advanced analytics can identify patterns across patient interactions, enrollment data, reimbursement activities, and adherence trends. These insights allow pharmaceutical manufacturers to anticipate potential barriers before they escalate.

For example, AI may identify patients who exhibit characteristics associated with therapy discontinuation, delayed treatment initiation, or repeated access challenges. Support teams can then intervene proactively with targeted outreach and personalized support.

This shift from reactive problem-solving to predictive engagement represents one of the most significant opportunities for PSPs. Rather than waiting for patients to raise their hands, pharmaceutical manufacturers can identify risks earlier and act before they impact outcomes.

Transforming Quality Through AI-Powered Call Analysis
One of the most immediate applications of AI within PSPs is quality monitoring. Traditionally, quality assurance teams review only a small percentage of patient interactions. Industry averages often range between 2% and 3% of calls reviewed due to resource limitations.

AI-powered call mining dramatically changes that equation. Using speech analytics and natural language processing, pharmaceutical manufacturers can evaluate 100% of patient interactions across communication channels. Rather than relying on limited sampling, support leaders gain comprehensive visibility into every conversation. This provides significant advantages.

Quality teams can identify compliance concerns more quickly, supervisors can detect coaching opportunities at scale, and program leaders can uncover recurring patient pain points, process inefficiencies, or emerging trends that might otherwise go unnoticed.

“AI will undoubtedly transform patient support, but its greatest impact may not be replacing the human touch—it may be creating more opportunities for it.”

Perhaps most importantly, call mining transforms patient conversations into actionable intelligence. Every interaction becomes a source of insight that can help improve the overall patient experience.

Enhancing Access Through Intelligent Virtual Assistants
Patients increasingly expect support to be available on demand. Intelligent Virtual Assistants (IVAs) are helping pharmaceutical manufacturers meet these expectations by providing immediate responses to common questions and guiding patients through routine processes.

When implemented effectively, IVAs can improve responsiveness, reduce wait times, and provide support outside traditional operating hours. They can help patients navigate enrollment processes, answer benefit-related questions, direct patients to appropriate resources, and escalate more complex inquiries to live support professionals.

The goal is not to replace human interaction; it is to ensure patients receive timely assistance while allowing nurse navigators to focus on higher-value engagements that require empathy, judgment, and problem-solving.

The most successful implementations create a seamless experience between digital and human support channels.

Preparing for Agentic AI
While much of today’s discussion focuses on automation and conversational AI, the next evolution is already emerging.

Agentic AI refers to systems capable of independently executing multi-step tasks, making decisions within defined parameters, and coordinating activities across workflows. Within PSPs, agentic AI may eventually help coordinate benefits investigations, initiate follow-up actions, manage patient communications, identify intervention opportunities, and support complex administrative workflows.

While technology continues to mature, patient support leaders should begin evaluating where autonomous capabilities may create value while ensuring appropriate governance, oversight, and compliance safeguards remain in place.

Pharmaceutical manufacturers that begin preparing now will be better positioned to capitalize on future advancements.

Training the Workforce of the Future
AI is also transforming how patient support teams learn and develop. AIpowered training personas and simulation environments allow agents to practice interactions with realistic customer scenarios before engaging with them live. These tools can simulate difficult conversations, complex access situations, emotional patient interactions, and adherence challenges.

As a result, pharmaceutical manufacturers can accelerate onboarding, improve consistency, and strengthen agent preparedness. Rather than replacing human expertise, AI helps develop it.

The Human Touch Remains Essential
As AI capabilities expand, one reality remains unchanged: healthcare is deeply personal. Technology can automate tasks, identify patterns, and improve efficiency. It cannot replace empathy, trust, compassion, or human understanding.

Patients facing uncertainty often need reassurance as much as information.

They need someone who can listen, adapt, and understand the context behind their concerns. The future of patient support will not be defined by choosing between AI and human engagement. It will be defined by how effectively pharmaceutical manufacturers combine the strengths of both.

The most successful PSPs will use AI to eliminate friction, generate actionable insights, and proactively address patient needs. At the same time, they will preserve the human interactions that build trust and improve outcomes. AI will undoubtedly transform patient support, but its greatest impact may not be replacing the human touch—it may be creating more opportunities for it.